FUT4

Alpha-(1,3)-fucosyltransferase 4 · P22083 · FUT4 on Sugi Atlas →

3,176 patent compounds predicted against FUT4, 2,589 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gallic Acid (SCHEMBL15012)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL35258)	1.00	1/20
Gallocatechin Gallate (SCHEMBL49461)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL161547)	1.00	1/20
Gallic Acid (SCHEMBL678990)	1.00	1/20
Gallic Acid (SCHEMBL1845406)	1.00	1/20
Epigalocatechin Gallate (SCHEMBL1853219)	1.00	1/20
Gallic Acid (SCHEMBL4918056)	1.00	1/20
Gallic Acid (SCHEMBL109154)	0.94	1/20
Gallic Acid (SCHEMBL135340)	0.94	1/20
Gallic Acid (SCHEMBL154210)	0.94	1/20
Gallic Acid (SCHEMBL210236)	0.94	1/20
Gallic Acid (SCHEMBL338356)	0.94	1/20
Gallic Acid (SCHEMBL438023)	0.94	1/20
Gallic Acid (SCHEMBL597299)	0.94	1/20
Gallic Acid (SCHEMBL617139)	0.94	1/20
Gallic Acid (SCHEMBL702575)	0.94	1/20
Gallic Acid (SCHEMBL990972)	0.94	1/20
Gallic Acid (SCHEMBL1060587)	0.94	1/20
Gallic Acid (SCHEMBL1065001)	0.94	1/20

Clinical trials — most relevant to FUT4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study	PHASE4	COMPLETED
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation	PHASE3	UNKNOWN
Vaccine Treatment for Surgically Resected Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
NG2 and DLL3 CAR-T Cells Targeting Melanoma	PHASE1/PHASE2	RECRUITING
Daratumumab in Combination With ATRA	PHASE1/PHASE2	COMPLETED
Cetuximab and Lenalidomide in Head and Neck	PHASE2	COMPLETED
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)	PHASE2	COMPLETED
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Safety and Efficacy Study of 90Y-hPAM4 at Different Doses	PHASE1/PHASE2	COMPLETED
GD2/CD56 Bi-specific CAR-T Cell Therapy	PHASE1/PHASE2	RECRUITING
Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS	PHASE1	RECRUITING
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies	PHASE1	COMPLETED
The Phase I Study of SIG001 Antibody on Cancer Therapy.	PHASE1	NOT_YET_RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors	PHASE1	COMPLETED
A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons	PHASE1	COMPLETED
The Correlation of Lewis Antigens With VTE	nan	NOT_YET_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)	nan	COMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases	nan	COMPLETED
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid	nan	UNKNOWN
CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer	nan	RECRUITING
Risk of Ovarian Cancer in Patients With a Pelvic Mass	nan	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain	nan	COMPLETED
Investigating Mucinase Activity in Airway Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a FUT4 binder may also engage these)

Protein	Name	Similarity
Q659K9	—	1.000	Q659K9 →
Q62994	—	0.989	Q62994 →
Q11131	—	0.983	Q11131 →
Q11127	—	0.979	Q11127 →
Q8HZR3	—	0.978	Q8HZR3 →
Q5U4P2	—	0.977	Q5U4P2 →
Q5SZI1	—	0.973	Q5SZI1 →
Q9EP78	—	0.971	Q9EP78 →
Q712G6	—	0.969	Q712G6 →
Q2TA57	—	0.969	Q2TA57 →
Q5T4W7	—	0.969	Q5T4W7 →
Q8NAG6	—	0.969	Q8NAG6 →
Q9Z0L2	—	0.968	Q9Z0L2 →
Q8HYJ3	—	0.968	Q8HYJ3 →
Q76KP1	—	0.968	Q76KP1 →
A7MBM2	—	0.968	A7MBM2 →
Q5VTJ3	—	0.967	Q5VTJ3 →
O00221	—	0.967	O00221 →
Q9WTM3	—	0.967	Q9WTM3 →
Q9GZZ7	—	0.966	Q9GZZ7 →
Q6AYE8	—	0.966	Q6AYE8 →
Q8NBR0	—	0.966	Q8NBR0 →
Q8NCW0	—	0.966	Q8NCW0 →
P56433	—	0.965	P56433 →
Q8N398	—	0.965	Q8N398 →
Q6ZW31	—	0.965	Q6ZW31 →
A1L515	—	0.965	A1L515 →
Q9WTL3	—	0.965	Q9WTL3 →
Q96RP7	—	0.964	Q96RP7 →
Q6XQG8	—	0.964	Q6XQG8 →